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Background: Thoracic ascending aorta aneurysms (TAA) are an important cause of mortality in adults but are a
relatively less studied subject compared to abdominal aortic aneurysms (AAA). The purpose of this review is
to explain the main aspects (etiology, pathophysiology, diagnosis) of this disease and to summarize the most
recent developments in its management.
Methodology: Literature was obtained through online health related search engines (PubMed, MEDLINE) by
including the following keywords: ascending aorta aneurysm, thoracic aneurysms, Marfan syndrome, bicuspid
aortic valve, familial thoracic syndrome, aortic dissection, aorta imaging and aortic aneurysm guidelines. We
included articles dating from 1980 to 2014.
Findings: Literature revealed how lethal this disease can be and how simple steps such as follow-up and prophy-
lactic surgery can signiﬁcantly reduce morbidity and mortality. This review also allowed us to realize the
many developments that have been made in recent years in the understanding of pathologic mechanisms of
this disease.
Conclusion: TAA is a silent disease that needs to be recognized early in its course and followed closely in order to
recommend appropriate preventive and prophylactic therapy in a timely manner.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The dilation of the ascending aorta is a common incidental ﬁnding
on transthoracic echocardiography performed for unrelated indications.
While the potential complications of aortic rupture and dissection are
well recognized, most physicians are trained for the treatment of heart
and coronary artery diseases, with limited knowledge and experience
in the optimal management of patients with a dilated ascending aorta.
The purpose of this article is to review the current understanding of
the etiology, diagnosis, medical management and timing of surgical
intervention in the patient with a dilated ascending aorta or ascending
thoracic aortic aneurysm (TAA).
1.1. Anatomy
The aorta is divided into two main segments: thoracic and abdomi-
nal. The thoracic aorta is further divided into 3 parts: ascending, arch
and descending. The ascending aorta originates beyond the aortic
valve and ends right before the innominate artery (brachiocephalict 1658, Montreal, Qc, H4N 0B6,
land Ltd. This is an open access articltrunc). It is approximately 5 cm long and is composed of two distinct
segments. The lower segment, known as the aortic root, encompasses
the sinuses of Valsalva and sinotubular junction (STJ). The upper
segment, known as the tubular ascending aorta, begins at the STJ and
extends to the aortic arch (innominate artery). More than 50% of TAA
are localized to the ascending aorta, which may affect either the aortic
root or tubular aortic segment [1].1.2. Deﬁnition of aortic aneurysm
Published data on arteries diameter in healthy population are often
scant or variable because of different imaging modalities used for
measurement. Nevertheless, by common convention, aortic dilatation
refers to a dimension that is greater than the 95th percentile for the
normal person age, sex and body size. In contrast, an aneurysm is
deﬁned as a localized dilation of the aorta that is more than 50% of
predicted (ratio of observed to expected diameter ≥1.5). Aneurysm
should be distinguished fromectasia,which represents a diffuse dilation
of the aorta less than 50% of normal aorta diameter.
An ofﬁcial cutoff for the deﬁnition of aortic dilatation has not
been determined because of the variability of this measure, but
most experts agree that ascending aorta size should be correlated
to size and gender. In addition, some authors suggest using the aortic
size index [2] which takes into account the body surface area, thuse under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and vice versa.
1.3. Epidemiology
Thoracic aortic aneurysms (TAA) and its associated complications
are life threatening clinical entities that rank in the top 20 leading
causes of mortality in the United States (15th leading cause of
death in people over 65 years old) (CDC, http://webapp.cdc.gov/
cgi-bin/broker.exe). Unfortunately, the mortality rate of patients
presenting with complications of TAA has remained relatively stable
in the last two decades, in contrast to the improved survival ob-
served in patients presenting with complications of coronary artery
disease (CAD). As Clouse et al. pointed out, the prognosis of patients
with TAA is indeed improved if they are treated before complications
occur [3].
The incidence of TAA has been reported to be only 5.9 cases per
100,000 person-years in the early 1980s, however recent advances in
imaging modalities, aging of the population, increased use of transtho-
racic echocardiography and routine screeninghave resulted in a twofold
increase in the incidence [4]. According to the CDC, the incidence of
ascending TAA is estimated to be around 10 per 100,000 person-years.
Women and men have similar incidences of thoracic aortic aneurysm
but the age at diagnosis is a decade higher in women (70s) than in
men (60s).
1.4. Pathophysiology
The aorta is an elastic vessel composed of three main layers: the tu-
nica intima, the tunica media and the tunica adventitia. The internal
elastic lamina separates the intima from the media.
Elastic ﬁber in themedial layer of the aorta allows continuous for-
ward ﬂow during the whole cardiac cycle. During systole, expansion
of the aorta allows kinetic energy from left ventricular contraction to
be stored as potential energy in the aortic wall. In diastole, recoil of
the aorta transforms the stored potential energy back to kinetic en-
ergy, propelling the blood distally into the arterial bed. With aging,
there is fragmentation of elastic ﬁber, smooth muscle dropout and
replacement by amorphous material (known as cystic medial degen-
eration), which leads to increased stiffness and weakening of the
aortic wall which predisposes to dilatation of the ascending aorta.
In addition, according to Laplace's law, the dilation of the aorta in-
creases wall tension, triggering vascular wall remodeling and even
further aortic dilatation.
Recent developments have helped better explain the cellular
changes that lead to aneurysmal ascending aortas. The different
conditions that cause TAAs either affect structural components of
the aortic wall or alter the intracellular signaling cascade that
maintains vascular wall integrity. The main culprit in this disease
seems to be the TGF-B1 signaling mechanism that is responsible
for activating matrix degradation through increased production of
plasminogen activators and release of matrix metalloproteinases
[5].
For example, mutations in ACTA2 alter the function of smooth
muscle cell actin and are responsible for 14% of inherited TAAs [6]. In
addition, the MYH11 gene affects the C-terminal coiled-coil region of
the smooth muscle myosin heavy chain, a speciﬁc contractile protein
of smooth muscle cells [7] and increases TAA formation.
Other mutations can affect both the structure and the metabolic
homeostasis of the vascular wall. For instance, the mutation of ﬁbrillin
1 in Marfan syndrome weakens the vascular wall given that it is a rein-
forcing structure [8] and it also alters the regulation of the bioavailability
of TGFB1 [9].
Other mutations affect the TGF-B signaling pathway directly by
affecting the TGF-B receptors such as in Loeys–Dietz syndrome
[10]. Other mutations alter the regulatory mechanisms that inhibitthe activity of the TGF-B pathway such as the mutation of GLUT10,
a glucose transporter whose deﬁciency is associated with arterial
tortuosity syndrome [11] or the mutation of the SMAD3 gene that
encodes a protein necessary for the signaling downstream of the
TGF-B pathway [12].
Many other structural anomalies andmetabolic alterations have also
been implicated in the pathogenesis of TAAs but will not be extensively
reviewed in this article.
1.5. Etiologies
The process of cystic medial degeneration can be either due to an
innate defect or an acquired one. As can be seen in Table 1, ascending
TAA is frequently seen with connective tissue diseases such as
Marfan syndrome, Ehlers–Danlos syndrome, or familial aneurysms
syndrome [13]. Data suggests that this process can also occur in con-
genital disease such as tetralogy of Fallot [14] and bicuspid aortic
valve (BAV). Hypertension and smoking appear to accelerate the
process by increasing elastolytic enzymes in the aortic medial layer
[13]. Atherosclerosis has long been considered as a second cause of
aortic aneurysm formation, with atheromatous plaques destroying
small muscle cells and elastic ﬁber architectures, resulting in weak-
ening of the aortic wall. However, this concept has recently been
challenged; and it is now thought that atherosclerosis is not a prima-
ry cause, but a concomitant process in the diseased medial layer of
the aortic wall [13].
Other less common etiologies can contribute to TAA formation.
These include post-traumatic aortic transection, aortic cannulation
post-CABG surgery, chronic aortic dissection, bacterial or syphilitic
infection and vasculitic aortitis. These uncommon etiologies are not
discussed in this review.
1.6. Risk factors
Different studies have shown that the ascending aorta diameter
signiﬁcantly correlates with age, waist circumference, smoking his-
tory and hypertension; the latter being themost prevalent risk factor
for acute aortic dissection [15]. In a recent study, mean carotid inti-
mal media thickness as well as epicardial adipose tissue were associ-
ated with ascending aorta dilatation [16]. In a study examining 833
autopsy cases, six risk factors (age, sex, body height, smoking histo-
ry, hypertension and severe atherosclerosis) have been associated
with ascending aorta dilations with age being the most important
predictor of dilatation [17].
2. Diagnosis
2.1. Presentation
Dilatation of the ascending aorta is a very indolent process as it
takes many years to develop and it is asymptomatic initially. In pa-
tients who develop an ascending aortic aneurysm secondarily to a
systemic disorder, signs of the primary disease are the ones who
lead the clinician to look for the dilatation such as in Marfan syn-
drome. Otherwise, this pathology remains quiet until its catastrophic
complications occur or when it is incidentally seen on cardiovascular
imaging related to other causes. We can prevent these complications
by screening asymptomatic patients. Feared events include aortic
dissection or rupture, pericardial hemorrhage, cardiac tamponade
and occlusion of aortic branches. In addition, some patients, in a less-
er proportion, can also develop intramural hematomas or penetrat-
ing aortic ulcers.
As shown in Tables 2.1 and 2.2, these complications do not manifest
at the same age or at the same ascending aortic size. They are greatly
dependent on the predisposing condition and, as discussed later, on
the management of this disease.
Table 1
Etiologies of ascending aortic dilatation.
Congenital Hereditary Acquired
Bicuspid aortic valve
Tetralogy of Fallot
Connective tissue disease
- Marfan syndrome
- Ehlers–Danlos syndrome
- Loeys–Dietz syndrome
- Arterial tortuosity syndrome
- Aneurysms osteoarthritis
syndrome
Hypertension
Infectious
- Syphilitic
- Bacterial infections
- Viral
- Fungal
Familial aortic syndromes
- Autosomal dominant
- Sporadic
Auto-immune
- Takayasu
- Behçet disease
- Idiopathic aortitis
Post-traumatic
Chronic aortic dissection
AV ﬁstula
Post-stenotic
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As can be seen in Table 3, many imaging modalities can be used to
image the ascending aorta. We will discuss the advantages and
disadvantages of each of these modalities in this section.
2.1.2. Chest X-ray
TAA produces a widening of the mediastinum characterized by a
width on AP ﬁlm of greater than 8 cm at the T4 or carinal level. In
the lateral view, there is loss of the retrosternal space. However,
this simple and non-invasive test is not neither sensitive nor speciﬁc.
CXR could be normal in 15–20% of patients with TAA or aortic
dissection.
2.1.3. Echocardiography
Transthoracic echocardiography (TTE) provides a simple non-
invasive technique to evaluate the aortic root, proximal ascending
aorta, aortic valve and left ventricular morphology and function
in the vast majority of patients. For aorta assessment, images
should be obtained in the parasternal long axis view and the aorta
size measured at the onset of the QRS complex at 4 levels of the as-
cending aorta: annulus, sinuses of Valsalva, ST junction, and as-
cending tubular aorta (maximal diameters). Aortic dimensions
can be obtained using a leading-to-leading edge technique [18].
Measurements obtained from two-dimensional images are pre-
ferred as m-mode techniques may underestimate the size of the
aorta due to translation of the heart during the cardiac cycle.
Even though TTE does not provide consistently an adequate im-
aging of mid and distal segments of the ascending aorta, nor does it
well visualize the descending aorta, it is the recommended imagingTable 2.1
Age of complication for TAA.
Mean age at presentati
(years)
Hypertensive 64.2
Marfan syndrome 24.5
34.4 (age at prophylactic
39.4 (age at aortic dissec
Bicuspid aortic valve 49
Familial (non syndromic) 56.8
Loeys–Dietz syndrome 19.8 (age at complicati
Ehlers–Danlos syndrome No datatechnique for screening of patients with suspected aortic aneurysm
(root or proximal aorta) and for follow-up. A recent study [19]
showed that TTE can substitute TEE in the follow-up of TAA dilata-
tion with both modalities having relatively the same accuracy and
a very little inter-observer variability.
Although, transesophageal echocardiogram (TEE) provides better
view of almost the entire thoracic aorta, it is a semi-invasive technique
and it is not the preferred routine study for follow-up or screening.
2.1.4. CT scan
Since the introduction of CT scanning in the 80s, it has become the
preferred imaging technique to deﬁne aortic anatomy and its side
branch vessels because of its easy accessibility and of its rapid results.
With 3D reconstruction, the accuracy is further enhanced for measure-
ment of aneurysms and the diagnosis of dissection, penetrating ulcer or
intramural hematoma. The sensitivity and speciﬁcity of angioscans have
increased greatly in the last few years reaching up to 100% [20], thus
becoming comparable to MRI. Recently, a published study [21] dem-
onstrated that dual source CT scan is as accurate as MRI in
documenting TAA diameters in patients with BAV and a stenotic
aortic valve which comes to reinforce the role of CT scanning in the
diagnosis of TAA dilatation.
The main disadvantages of CT scanning are the radiation expo-
sure and the risks related to contrast injection such as contrast in-
duced nephropathy (CIN), carcinogenicity and teratogenicity.
While CIN can be easily prevented with adequate hydration and re-
duction of contrast volume, carcinogenicity remains an important
issue to consider especially in younger patients (i.e. Marfan syn-
drome patients) who require serial evaluations even in the context
of newer generation low dose CT scanners. For this reason, screen-
ing with CT scanning is not routinely recommended, but it is the
imaging method of choice to diagnose complications of ascending
TAA dilatation and for preoperative visualization of the entire aor-
tic anatomy.
2.1.5. MRI
MR angiography is an imaging modality that provides accurate
measurement and deﬁnition of the entire aorta anatomy. Combined
with cardiac MRI, this technology can better assess ventricular func-
tion, aortic valve function and aortic root anatomy. While it has the
advantages of not requiring any radiation exposure, it is a less acces-
sible and amore time consuming imaging technique. In addition, it is
contraindicated in patients having metallic parts in them and in pa-
tients with advanced renal failure because of the possible risk of sys-
temic nephrogenic ﬁbrosis related to gadolinium injection.
3. Natural history
Normal aorta grows slowly with age. From the Framingham Heart
Study (echo sub-study), aorta diameter increases 0.1 cm per 10 yearson Source
(Davies, Kaple et al., 2007) [16]
(Jondeau, Detaint et al., 2012) [17]
surgery)
tion)
(Davies, Kaple et al., 2007) [16]
(Albornoz, Coady et al., 2006) [18]
ons) (Loeys, Schwarze et al., 2006) [8]
No data
Table 2.2
Diameter of ascending aorta at timing of complications.
Mean size at
complications
(mm)a
Source
Hypertensive 60 (Davies, Kaple et al., 2007) [16]
Marfan syndrome 51 (Roman, Rosen et al., 1993) [19]
56 (Kornbluth, Schnittger et al., 1999) [20]
50–59 (Jondeau, Detaint et al., 2012) [17]
Bicuspid aortic valve 52 (Davies, Kaple et al., 2007) [16]
Familial (non-syndromic) No data No data
Loeys–Dietz syndrome 40–50 (Loeys, Schwarze et al., 2006) [8]
Ehlers–Danlos syndrome No data No data
a It is to be noted that the risk of complications is higher for bigger diameters in each of
the preceding conditions.
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served for the tubular portion of the ascending aorta [23]. By the age of 75,
normal ascending aorta diameter is approximately 3.6–3.7 cm forwomen
(BSA: 1.95 m2) and 4.1–4.2 cm for men (BSA: 2.35 m2).
3.1. Hypertension related ascending thoracic aortic aneurysms
Nearly all studies found that hypertension increases ascending aorta
dilatation in pre-existing TAAs and predisposes to the formation of TAA.
Unlike inherited forms of ascending aortic aneurysms, hypertension re-
lated TAAs complicate at diameters over 6.0 cm and the risk of compli-
cations increases exponentially with the further increase in diameter
[13].
Once the aorta becomes aneurysmal, its rate of growth is some-
how accelerated and is strongly inﬂuenced by its size. The database
from the Yale Center shows that aneurysms of the thoracic aorta
grow at approximately 0.12 cm/yr (all patients confounded). The an-
nual growth varies from 0.08 cm for small aneurysm (4.0 cm) to
0.16 cm for large aneurysm (8 cm) [24]. The rate of growth is also af-
fected by the location of aneurysm. Aneurysms arising from ascend-
ing aorta grow slower (0.07 cm/yr) than the one from descending
thoracic (0.19 cm/yr).
3.2. Bicuspid aortic valve (BAV)
Bicuspid aortic valve (BAV) disease is the most common congen-
ital heart disease, occurring in 1–2% of the population. Bicuspid aor-
tic valve is associated with valvular complications (aortic stenosis or
regurgitation) as well as vascular complications such ascending
aorta dilatation beyond the sinotubular junction and up to 33% will
develop serious complications [25]. Up to 83% of patients with BAV
will develop ascending aorta dilatation [26]. Nistri et al. found that
52% of patients with a normally functioning bicuspid valve have aor-
tic dilatation [27].Table 3
Advantages and disadvantages of different imaging modalitiesa.
Ultrasound
Advantages Widely available
Allows for estimating valve function
No radiation exposure
Disadvantages Time consuming compared to CT-scan (center dependent)
Inter-observer variability
Arch not visualized
Difﬁculty visualizing portions distal to the sinotubular junction
a Chest X-ray has not been included in this table for the reasons outlined below.While the valvular complications are directly related to the valve
anatomy and its underlying embryological defects, the pathophysi-
ology of the vascular complications is still under debate. Aortic dila-
tation could be easily attributed to hemodynamic abnormalities
across an abnormally shaped valve but many studies seem to show
that valvular dysfunction is not signiﬁcantly related to increased aor-
tic size. For instance, Ferencik and Pape showed that in patients with
BAV with normal valve function, progressive aortic dilatation was
more severe than in patients with tricuspid aortic valve (TAV) [28].
In a case–control study done by Keane et al., BAV patients were
matched with TAV patients with similar valve function (AR, AS, nor-
mal) and the results showed that patients with BAV had aortic dila-
tation at a younger age and earlier than their matched controls
[29]. Most studies done so far seem to show an underlying congenital
anomaly in the aortic media associated with BAV that predisposes
these patients to develop aortic dilatation with an aggravation in-
duced by the valve dysfunction.
Very few studies succeeded in establishing a growth rate pattern for
patients with BAV, and the evidence remains contradictory. A prospec-
tive TEE study has compared the growth rates of the dilated ascending
aorta (4.0–6.0 cm) between patients with normal functioning aortic
bicuspid and tricuspid valve. Among the 113 patients studied, 86 had bi-
cuspid and 27 had tricuspid valve and therewasnodifference in the rate
of growth between the two groups [30]. In contrast, another study in-
volving 514 patients comparing patients with BAV (70) to patients
with TAV(445) showed that patients with BAV had a higher growth
rate (0.19 cm/yr compared to 0.14 cm/yr) and higher surgical repair
rate than TAV patients (72.8% vs 44.8%). In addition, a recent study at
the Montreal Heart Institute showed that ascending aortas in patients
with BAV had a growth rate of 0.1 cm per year 1 cm beyond the
sinotubular junction [31].
While it may seem that the natural history of TAA in patients with
bicuspid aortic valve disease remains ill-deﬁned, there seems to be a
great tendency towards faster growth rate in this population.3.3. Marfan syndrome
Marfan syndrome, ﬁrst described by Antoine Marfan in 1896, is a
connective tissue disorder with manifestations mainly involving the
cardiovascular, respiratory, skeletal and ocular systems. It is caused
by a mutation of the FBN-1 gene that is inherited in an autosomal
dominant pattern, although, 25% of cases seem to be sporadic.
While Marfan syndrome predisposes to many other conditions, its
most serious complications are related to aortic valve regurgitation
and ascending root dilatation. Aortic dissection constitutes the
most common cause of death in these patients. Up to 80% of patients
with Marfan syndrome have ascending TAA dilatation [32]. Plus,
women often complicate at smaller ascending aorta size compared
to men [33].
Different studies have tried to establish the growth rate of the as-
cending aorta in these patients. As shown in Table 4, the resultsCT-scan MRI
Rapidly available
Nearly 100% speciﬁc and sensitive
Can diagnose dissection
Can visualize entire aorta
Nearly 100% speciﬁc and sensitive
No radiation exposure
Can visualize entire aorta
Radiation exposure
Contrast nephropathy
Time consuming compared to CT-scan
Many contraindications
Contraindicated in advanced renal failure
More expensive
Table 4
Mean increase in aorta size in patients with Marfan syndrome.
Source Sample
size
Growth rate (mm per year)a
Men Women
(Jondeau, Detaint et al., 2012) N = 762 0.50 ± 0.89
(Lazarevic, Nakatani et al., 2006) N = 43 1.5 ± 1.3
(Meijboom, Timmermans et al., 2005) N = 221 0.42 0.38
(Kornbluth, Schnittger et al., 1999) N = 57 Up to 2 mm per year
(Shores, Berger et al., 1994) N = 70 0.84
(Roman, Rosen et al., 1993) N = 113 1.4 ± 0.5 (complications group)
0.9± 0.8 (no complications group)
(Hwa, Richards et al., 1993) N = 40 1.5 1.8
0.36 0.27
a Compared to the 1 mm per decade observed in normal patients (refer to natural his-
tory section).
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The largest study on this issue (n= 762) by Jondeau et al. shows that
mean annual ascending aorta growth rate is 0.050 +/− 0.089 cm
[34]. It has also been noted in certain studies that there are two spe-
ciﬁc subsets of patients in terms of growth rate: fast growers and
slow growers. In a study by Meijboom et al., 1 in 7 men had a faster
yearly growth rate (0.15 cm compared to 0.036 cm) and 1 in 9
women (0.18 cm compared to 0.027 cm) [33]. Higher diastolic and
systolic blood pressure, older age and larger initial aorta size were
all associated with being a “fast grower” as shown in another related
study by Lazarevic et al. [35] and they were associated with a higher
rate of complications which are: aortic dissection, aortic regurgita-
tion and death. In the study by Roman et al., the extent of the dilata-
tion was also associated with a higher rate of complications (33% in
generalized dilatation compared to 6% in dilatation conﬁned to the
sinuses of Valsalva) [32].
3.4. Familial thoracic syndromes
Genetic predisposition other than Marfan syndrome appears to
be linked with the development of ascending TAA. Biddinger et al.
were the ﬁrst who reported familiar aggregation of TAA [36]. In this
study, patients with family history of TAA, aortic dissection or sud-
den death exhibited higher prevalence of TAA development and sud-
den death. Recently, similar studies support the role of genetic
factors in the familial aggregation of TAA [13,37,38]. Albornoz et al.
demonstrated that 21.5% of TAA was found in patients with family
history of TAA [37]. It seems to be transmitted in an autosomal dom-
inant pattern with variable degree of penetrance. The following mu-
tations have been associated with TAA and dissection: MYH11,
MYLK, SMAD3 and ACTA2 [39]. The age at presentation of complicat-
ing TAA or diagnosis of TAA is different as compared to patients with
Marfan syndrome or patients with sporadic TAA. They are older than
Marfan group but younger than sporadic group. The observed annual
growth of TAA for familial TAA is 2.1mm/yr, which is higher than any
other subgroups of population. In some cases, familial TAA appears to
be an aggressive aortic disease and family history of TAA, aortic dis-
section or sudden death needs to be considered as risk factor for
rapid growth of TAA and its complications.
3.5. Loeys–Dietz syndrome
Loeys–Dietz syndrome is an autosomal dominant genetic disor-
der mainly associated with mutations of the genes responsible for
the transforming growth factor B receptors 1 and 2. It is a rather
rare disease characterized by the triad of hypertelorism, a biﬁd
uvula, cleft palate or both, and generalized arterial tortuosity with
widespread vascular aneurysm and dissection [11]. This disorder
is nearly always associated with aortic root aneurysm and they
tend to have complications very early on in life. In the study by
Loeys et al. the mean age of death of these patients was at 26 and
was caused by thoracic aortic dissection and the mean age for
ﬁrst vascular surgery was 19.8 years. In addition, women with
this disease have higher tendency to have aortic dissection during
pregnancy.
3.6. Ehlers–Danlos syndrome (EDS)
Ehlers–Danlos regroups a multitude of connective tissue disor-
ders characterized by laxity of the Joints and skin disorders. Up to
28% of patients with EDS (all types confounded) present with as-
cending aorta dilatation [40]. This population has not been exten-
sively studied but the associated TAA seems to be of little clinical
importance as a recent retrospective study suggested that these
aortas seem to normalize in size when children with EDS become
adults [41]. However, type IV Ehlers–Danlos syndrome (autosomaldominant disorder) is characterized by characteristic skin manifes-
tations associated with arterial, uterine and intestinal dissection
and rupture [42]. Arterial complications are usually preceded by
aneurysm formation but they can also occur spontaneously. This
syndrome is associated with the COL3A1 mutation and the diagno-
sis can be made by DNA ampliﬁcation or by collagen analysis.
3.7. Arterial tortuosity syndrome
Arterial tortuosity syndrome is an autosomal recessive disorder
characterized by tortuosity and aneurysm formation in the major
arteries caused by a deﬁciency in glucose transporter GLUT 10 causing
an upregulation of TGFBR1 signaling [11].
3.8. Aneurysms osteoarthritis syndrome
Aneurysms osteoarthritis syndrome is an autosomal dominant
syndromic characterized by thoracic aortic aneurysms and dissections
associatedwith the presence of arterial aneurysms, early-onset osteoar-
thritis and cutaneous manifestations. AOS is caused bymutations in the
SMAD3 gene [43,44].
4. Management
4.1. When to intervene
As has been previouslymentioned, complications of ascending aorta
aneurysms can be disastrous even if diagnosed promptly and properly
managed. It is therefore essential to diagnose a pathologically dilated
ascending aorta in a timely fashion and to ensure a proper follow-up
in order to start medical therapy and recommend prophylactic surgical
repair.
Elective surgery is themainstay “curative” treatment. Several studies
have demonstrated the reduction in mortality associated with prophy-
lactic surgery (Table 5). Corrective surgery is recommended when the
aorta reaches a size where the risk of complications equals or exceeds
the risk related to the surgery.
There have been many studies that tried to establish a speciﬁc
size at which surgery should be performed, but it has been shown
that this criterion depends on the underlying pathology, the rate of
growth, the family history and to some extent the individual mor-
phology of each patient. A retrospective study (that included a few
patients with Marfan syndrome) showed that the median size asso-
ciated with an increased risk of aortic dissection, rupture or sudden
death was 6.0 cm [45]. In the same study, we see that the odds
ratio of acute dissection for an aorta between 5.0 and 5.9 cm was
not signiﬁcantly increased but that it jumps to a statistically signiﬁ-
cant 8.84 when it exceeds 6.0 cm.
It is therefore safe to recommend prophylactic surgery when the
aorta reaches a diameter of 5.5 cm unless the patient falls under the
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tory or fast growers in accordancewith the newest American guidelines
[46].
Some authors have even cited the need to be more aggressive in
the criteria for elective repair citing data from the International Reg-
istry of Aortic Dissection [47] showing that 60% of aortic dissections
occurred in aortas with diameters under 5.5 cm and that 40% of them
had diameters under 5.0 cm. These results led some experts to devel-
op other measures that can possibly better predict the risk of compli-
cations. For example, a novel method that takes into account the
body surface area called the aortic size index (ASI), measured by
MRI, by dividing the maximal aortic diameter with the body surface
area [2]. This formula allowed to identify 3 different risk groups:
those with an ASI higher than 4.25 cm/m2 experienced a sevenfold
increase in the incidence of aortic complications. This index allows
a certain individualization of the size at which people should be rec-
ommended surgery.
As of today, it is recommended to offer prophylactic ascending aorta
repair to patientswithout predisposing conditions other than hyperten-
sionwhen the aorta reaches 5.5 cm or if the growth rate exceeds 0.5 cm
per year or if patient is undergoing another major cardiac surgery with
an ascending aorta over 4.5 cm.
As has been already mentioned in this review, patients with
Marfan syndrome tend to have acute aortic syndromes at a younger
age and at smaller aortic diameters than other patients (refer to
Table 2.2). The newest American guidelines recommend prophy-
lactic surgery for patients with Marfan syndrome in 6 settings [46]:
1 When the aorta reaches a diameter of 5.0 cm.
2 When the aorta reaches a diameter of 4.5 cm with either a positive
family history of complications.
3 When the patient is undergoing aortic valve replacement, if the aorta
exceeds 4.5 cm.
4 Associated signiﬁcant aortic valve regurgitation, if the aorta exceeds
4.5 cm.
5 When the annual rate growth exceeds 0.5 cm.
Women with childbearing potential (see section on pregnancy).
Some references even suggest lowering the threshold for surgery
to all patients with Marfan syndrome to 4.5 cm based on data show-
ing that some dissections occur below the threshold aforementioned
and given the reduction of mortality associated to the surgery in high
volume centers. Choice of surgical procedure is discussed in the fol-
lowing section.
For patients born with a bicuspid aortic valve, data is still some-
what contradictory about the diameter at which complications
occur. It is now widely accepted that this is a heterogeneous popula-
tion. Therefore, there is variability with the determination of a spe-
ciﬁc diameter at which the risk of complications increases. Most
centers recommend elective replacement when the ascending aorta
reaches 5.0 cm. Choice of surgical procedure has not been extensive-
ly studied.
In patients diagnosed with Loeys–Dietz syndrome, complications
from TAA occur at a much younger age and at smaller ascending aorticTable 5
Mortality rates for timing of surgical therapy.
Sample size
Gott et al. NEJM 1999 (M)a 675
Coady et al. J thorac Surg 1997 230
Achnek et al. Ann Thorac Surg 2007 506
Kallenback et al. Circulation 2005 284
a (M) = studies on patients with Marfan syndrome.diameters than most other patients, thus requiring even more aggres-
sive prophylactic therapy. The authors of the main study on aneurysm
syndromes in patients with Loeys–Dietz syndrome recommend pro-
phylactic surgery at experienced centers when the aorta reaches
4.0 cm [10]. Likewise, the latest guidelines from the ACCF recommend
prophylactic surgery when the ascending aorta reaches 4.2 cm
(measured by transesophageal ultrasound) albeit being based on a “C”
level of evidence [46].
4.2. International recommendations
Tables 6, 7 and 8 compare Canadian, European and Japanese
guidelines in the management of ascending TAA in general as well as
in patients with Marfan syndrome or patients with a BAV. As can be
noticed, all international guidelines recommend prophylactic surgery
for TAA at sizes somewhat equivalent.
4.3. Medical management
If diagnosed early, mild to moderate dilated ascending aortas can
certainly beneﬁt directly frommedications such as beta blockers and
ACE inhibitors. In addition, it is very important to prevent and treat
risk factors such as hypertension and metabolic syndrome. There
is no ofﬁcial recommendation for the target blood pressure, but
it would be preferable to aim for blood pressure under 120/
80 mm Hg [48].
According to ACC guidelines, “antihypertensive therapy should be
administered to hypertensive patients with thoracic aortic disease to
achieve a goal of less than 140/90 (patients without diabetes) or less
than 130/80 (patients with diabetes or chronic renal disease) to reduce
the risk of stroke,myocardial infarction, heart failure and cardiovascular
death” [46].
In patients with Marfan syndrome, a landmark trial by Shores et al.
[49] demonstrated the efﬁcacy of the beta blocker propranolol in
reducing the rate of dilation of the ascending aorta (0.023 cm per year
compared to 0.084 cm per year with p b 0.001) as well as increasing
survival. The physiological effect of beta blockers on the natural history
of the dilated ascending aorta is not clearly understood, and a combina-
tion of reduced wall stress and vascular remodeling has been proposed.
As mentioned earlier, patients with mildly dilated ascending aorta are
those who beneﬁt the most from beta blockade as shown in a study
by Haouzi et al. [50].
In addition, many authors have shown interest in the effect of angio-
tensin converting enzyme inhibitors (ACEIs) on the rate of dilation of
TAA. In one study, the addition of perindopril to beta-blockers signiﬁ-
cantly reduced the aortic diameter as well as the aortic stiffness in a
small sample of 10 patients with Marfan syndrome [51]. This ﬁnding
is also corroborated by another study, in which beta blockers are com-
pared to the ACEI enalapril [52], the latter showing slower rate of aortic
growth, fewer adverse outcomes and decreased side effects in patients
with Marfan syndrome. The effect of ACEIs is thought to be due to the
decreased activity of the angiotensin II receptors which increase cystic
medial degeneration.Elective
(N7 days)
Urgent
(1–7 days)
Emergent
(b24 h)
1.5% 2.6% 11.7%
4.3% 20.5%
4.4% 21.6%
1.3% 9.3 ± 2.5%
Table 6
Comparison of national guidelines for themanagement of TAA in patients without any ge-
netic predisposition.
Canadian society for
vascular surgery
Japanese Circulation
Society 2011 guidelines
ESC 2007 guidelines
“Intervention should be
considered when the
diameter of a thoracic
aortic aneurysm reaches
5.5 cms in men, and 5.0 in
women. Smaller aneurysms
under surveillance typically
grow by 10% per year.
Faster growing aneurysms
should be considered for
intervention sooner than
the usual operative
threshold.”
http://canadianvascular.ca
The following situations
warrant surgical
intervention:
• Aneurysms with a
maximum minor-axis
diameter of 60 mm or
greater
• Aortic aneurysms ac-
companied by pain
where the maximum
minor-axis diameter is
50 to 60 mm
The following situations
warrant surgical
intervention:
• Aortic root diameter
greater than 55 mm.
• “For patients who
have an indication for
surgery on the aortic
valve, lower thresh-
olds can be used for
combining surgery on
the ascending aorta.”
(Group 2013) (Vahanian, Baumgartner
et al. 2007) [44]
Table 8
Comparison of national guidelines for the management of TAA in patients with bicuspid
aortic valve.
Canadian
guidelines
Japanese
guidelines
ESC 2012
Based on American
guidelines
Based on American
guidelines
The following situations warrant surgical
intervention:
• Ascending aorta diameter greater than
50 mmwith any of the following
risk factors:
1. Coarctation of the aorta
2. Systemic hypertension
3. Family history of dissection
4. Progressive dilation of more than
2 mm per year as conﬁrmed by
repeated measurements
(Vahanian, Alﬁeri et al., 2013) [44]
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COMPARE trial (prospective randomized study which included 233 pa-
tients with Marfan syndrome) revealed that losartan slowed aortic root
enlargement [53]. However, the study did not show a reduced rate of
events in the treatment group. This larger study conﬁrms the ﬁndings
of a smaller study (n = 17) that showed a beneﬁcial effect of losartan
on the rate of progression of TAAs [54].
While the use of Statin has been soaring in the past decade for the
treatment of abdominal aortic aneurysms (AAA), no study has found a
beneﬁcial effect on the outcomes associated with TAA.
Most studies have examined the effect of long-termmedical ther-
apy on the progression of idiopathic aortic dilation in patients with
Marfan syndrome. However, there are very few studies on patients
with other etiologies. Thus, it is unclear whether extrapolation of
the results of patients with Marfan syndrome can be done. Neverthe-
less, it is very important to encourage cardiovascular risk factor
reduction in patients with TAA especially hypertension and
dyslipidemia.
4.4. Surgical intervention
As has been already mentioned, surgery and ideally prophylactic
surgery remain the cornerstone of the treatment of the pathologicallyTable 7
Comparison of national guidelines for the management of TAA in patients with Marfan syndro
Canadian Cardiovascular
Society 2009 Consensus
Japanese Cir
2011 guideli
The following situations warrant surgical intervention:
• A maximal aortic root/ascending aorta diameter of greater than 50 mm.
• A maximal aortic root/ascending aorta diameter of greater than 45 mm to
50 mm with the following:
1. Rapid aortic root growth of more than 5 mm per year.
2. Progressive aortic regurgitation, especially if the surgeon believes the aortic
valve can be spared and an aortic valve-sparing procedure is planned.
3. Family history of premature aortic dissection of less than 50 mm.
4. Severe mitral valve regurgitation that requires surgery.
• A maximal aortic root/ascending aorta diameter of greater than 44 mm if
pregnancy is desired.
• A maximal dimension of other parts of the aorta of 50 mm to 60 mm or
progressive dilation.
• Severe mitral regurgitation with symptoms or progressive LV dilation/
dysfunction as per the current guidelines on valvular heart disease.
The followin
intervention
• Aortic roo
diameter e
• Aortic root
a history or
aortic root
• Aortic root
plating pre
is 40 mm o
(Silversides, Kiess et al., 2010) [45] (Group 2013dilated ascending aorta. Different surgical procedures can be performed
depending on the site of aortic dilation and the function of the aortic
valve. Dilation without implication of the Valsalva sinuses can be man-
aged by tube graft replacement, however when the sinuses of Valsalva
are involved, the Bentall procedure (composite valve graft replacement
with re-implantation of the coronary arteries) or the valve sparing
procedure can be performed [55]. The valve sparing procedure can be
done following the David technique (aortic valve reimplantation) or
the Yacoub technique (aortic valve remodeling). The David technique
is the one used preferentially [56]. In some cases, the Ross procedure
can also be performed, if the native aortic valve is diseased and cannot
be reimplanted.
In general, all three procedures are associated with lower mortality
and morbidity if performed electively. Post-operative morbidities in-
cluding stroke, myocardial infarct, bleeding and aortic insufﬁciency
have been estimated at less than 5%.
Choice of procedure depends on many factors, but, in general,
most studies show an early and late mortality and morbidity advan-
tage associated with the valve sparing surgery at the expense of a
slightly higher re-operation rate. As Tables 9 and 10 show, there is
decreased 30-day and 5 years mortality in patients who undergo
the valve sparing procedure. As previously stated, freedom from re-
operation for aortic insufﬁciency is slightly lower in patients who
undergo the valve sparing procedure (VSP). In one study [57]me.
culation Society
nes
ESC 2010
g situations warrant surgical
:
t replacement when aortic root
xceeds 45 mm
replacement in an individual with
family history of dissection when
diameter is 40 mm or greater
replacement in women contem-
gnancy when aortic root diameter
r greater
The following situations warrant surgical
intervention:
• Ascending aorta diameter greater than 50 mm.
Consider surgery if greater than 45 mm.
• Ascending aorta diameter between 46 and 50 mm
with:
1. Family history of dissection
2. Progressive dilation of more than 2 mm per
year as conﬁrmed by repeated measurements
3. Severe AR or MR
4. Desire of pregnancy
• Patients should be considered for surgery if
other parts of the aorta are over 50 mm.
) (Baumgartner, Bonhoeffer et al., 2010) [46]
Table 9
Mortality rates for surgical repair with valve replacement.
Sample 30 days mortality 5 years mortality 10 years mortality
Gott et al. NEJM 1999 (Marfan patients) [53] 675 3.5%–4.8% – –
Karck et al. J Thorac Cardiovasc Surg 2004 (Marfan patients) [52] 119 6.8% 11 +/− 4% –
98 E. Saliba et al. / IJC Heart & Vasculature 6 (2015) 91–100following patients who underwent either VSP or valve replacement
surgery (VRS), there is an increased freedom from re-operation in
patients with VRS (96%) compared to patients who underwent VSP
(63%). In another study [1], freedom from re-operationwas approximate-
ly 90% in patients who underwent VSP.4.4.1. Surgical management in patients with Marfan syndrome
Several studies have examined the beneﬁts of VSP versus VRP in
patients with Marfan syndrome (refer to Tables 9 and 10). While
some retrospective single center studies found that the VSP shows
superiority in survival and morbidity, there seems to be a tendency
towards higher rates of re-operation and re-exploration therapy
[58]. In a 2011 meta-analysis analyzing data from 1385 patients,
there was a statistically signiﬁcant difference in reintervention
rates in patients undergoing VRP [59]. In addition, some authors
have reported that patients with Marfan syndrome might not be
ideal candidates for VSP because they believe that these patients
have innate structural disorders of the aortic valve requiring replace-
ment later in life.5. Ascending aortic dilatation and pregnancy
There have been many cases reported about ascending aorta dila-
tation during pregnancy and the increased rate of complications dur-
ing this period.While this subject is not very well studied, pregnancy
seems to predispose to arterial wall degeneration by the excess re-
lease of estrogen and progesterone [60]. In select women, this pro-
cess is aggravated by the very well known cardiovascular changes
during pregnancy (increased circulating volume, increased stroke
volume and increased heart rate). In addition, women with predis-
posing conditions such as those mentioned in Table 3 (Marfan syn-
drome, BAV, etc.) are at increased risk of complications during
pregnancy.
According to the newest guidelines, all pregnant women with
TAA should be under strict blood pressure control (b120/
80 mm Hg) and a monthly or bi-monthly echocardiographic mea-
surement of the ascending aorta should also be performed to follow
the growth rate [46].
While there were no ofﬁcial guideline and no prospective study
to conﬁrm it, most experts agree that women who wish to become
pregnant should get prophylactic surgery at earlier stages of their
disease. For example, patients with Marfan syndrome should get
prophylactic repair when the ascending aorta reaches 4.0 to 4.5 cm
and patients with BAV should get it when the aorta reaches 4.5 to
5.0 cm.Table 10
Mortality rates for surgical repair with valve sparing surgery.
Sample
Gott et al. NEJM 1999 (Marfan patients) [53] 675
David et al. Journal of Thoracic and Cardiovascular surgery 2006 220
Karck et al. J Thorac Cardiovasc Surg 2004 (Marfan patients) [52] 119
Kallenbach et al. [1] 284
Kallenback et al. [54] (Marfan patients) 356. Follow-up and screening
As noted above, the natural history of TAA is that of progressive ex-
pansion. Patients with aortic root or ascending aortic dilation that has
not yet exceeded the threshold for surgical intervention require serial
evaluations. The size of the aortic root and ascending aorta should be
evaluated annually or biannually, although more frequent studies are
warranted (3–6 months) when the aorta exceeds 4.5 cm or the growth
rate N 0.5 cm/yr. Patient who is newly diagnosed of TAA needs to have
another imaging in 6 months to determine the growth rate. If patient
is a fast grower, imaging assessment needs to be every 3–6 months.
Otherwise if TAA is stable, imaging will be annually.
Patientswhoalready had their TAA repair still requiremedical atten-
tion. These patients could develop aneurysm in other segments of aorta,
particularly in patients with chronic dissection at the distal anastomosis
of tube graft. It has been reported that patients with chronic dissection
had late reoperation rate as high as 30%. Annual imaging assessment
of the entire aorta is recommended.
According to ACC guidelines, all patients withMarfan syndrome and
Loeys–Dietz syndrome should receive screening for ascending TAA
when diagnosedwith this disease and6months thereafter to determine
the rate of growth. Afterwards, annual imaging is recommended to doc-
ument the progression of the dilation. If the aorta reaches 4.5 cm or if
the rate of progression increases, the imaging follow-up should become
more frequent [46].
As mentioned earlier, familial thoracic aneurysm disease can occur
in different patterns. It is therefore reasonable to recommend screening
for ﬁrst degree relatives of affected people.
All patients with a BAV should undergo TAA screening. Familymem-
bers of these patients should be screened for BAV.
Screening of ﬁrst-degree relatives is considered warranted for many
of these conditions; however, at what age the investigation should be
started, how often the imaging should be repeated and how long the
screening should last are still debatable at the present time as well as
the cost effectiveness of the methods.7. Exercise restriction
Patients with aorthopathy associated withMarfan syndrome should
avoid isometric exercise because of sustained elevation of blood
pressure andwall stress applied on aortic wall during exertion [61]. Iso-
metric exercises include weight lifting, sit-ups, and push-ups. Patients
are encouraged to perform aerobic exercisewithmoderation. These rec-
ommendations should be given to all patients with other aortopathies
since the shear stress needs to be kept minimal once aorta becomes
aneurysmal.Early mortality 5 years mortality 10 years mortality
0% – –
– 6 +/− 1% 88 +/− 3%
0% 4 +/− 4% –
3.2% 9.3 +/− 2.5% –
0% 8.5% –
99E. Saliba et al. / IJC Heart & Vasculature 6 (2015) 91–1008. Conclusion
Ascending aortic aneurysm is a lethal disease. Elective surgical repair
remains themainstay for themanagement of symptomatic aneurysmor
asymptomatic aneurysm ofwhich the diameter N 5.5 cm. Lower thresh-
old of aortic diameter for surgery should be considered for patients with
aortopathy related to congenital etiologies. Medical treatment aswell as
lifestyle changes and risk factor control, and serial imaging assessment
of aortic aneurysm constitute the second part of the management of
these patients.
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